TERTp mutation is associated with a shorter progression free survival in patients with aggressive histology subtypes of follicular-cell derived thyroid carcinoma.
Gustavo C PennaAna PestanaJosé Manuel CameselleDenise MomessoFernanda Accioly de AndradeAna Paula Aguiar VidalMario Lucio Araujo JuniorMiguel MeloPriscila Valverde FernandesRossana CorboMario VaismanManuel Sobrinho-SimõesPaula SoaresFernanda VaismanPublished in: Endocrine (2018)
TERTp mutation appears be an indicator of both persistence and progression of structural disease after initial therapy in aggressive variants of TCDFC, and associates with a shorter progression free survival regardless of the therapy employed.